Drug and Challenge Dose Selection The selection of an incretin mimetic dose for evaluation in neurotrophic, neuroprotective, and inflammatory studies across SH-SY5Y, HMC3, and IMG cells was based on pilot doseresponse studies that were focused on identifying the threshold concentration to provide the biological action of interest, and this dose was then used across single, dual, and triple receptor agonists to allow their side-by-side comparison at an equimolar concentration
Our Scottsdale medical weight loss team specializes in helping you lose weight using prescription-based injections and personalized care
In the Phase 3 TRIUMPH-1 trial reported May 21, 2026, the 12 mg arm produced mean body-weight reduction of 28.3% at 80 weeks, with extension data reaching 30.3% at 104 weeks [1][2]
Screening and follow-up are not optional.
Notably, the FDA's enforcement actions do not extend to legitimate 503A pharmacies operating under state supervision and physician oversight